Simon, Amy

A highly durable RNAi therapeutic inhibitor of PCSK9

Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery

Cited by 768

Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria

Balwani, M., Sardh, E., Ventura, P., Peiró, P. A., Rees, D. C., Stölzel, U., Bissell, D. M., Bonkovsky, H. L., Windyga, J., Anderson, K. E., et al. (2020) · New England Journal of Medicine

Porphyrin Metabolism and DisordersNeonatal Health and Biochemistry

Cited by 608

Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification

Chan, A., Liebow, A., Yasuda, M., Gan, L., Racie, T., Maier, M., Kuchimanchi, S., Foster, D., Milstein, S., Charisse, K., et al. (2015) · Molecular Therapy — Nucleic Acids

Porphyrin Metabolism and DisordersRNA Interference and Gene Delivery

Cited by 128